Xencor, Inc. (XNCR) News
Filter XNCR News Items
XNCR News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
XNCR News Highlights
- For XNCR, its 30 day story count is now at 2.
- Over the past 19 days, the trend for XNCR's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
Latest XNCR News From Around the Web
Below are the latest news stories about XENCOR INC that investors may wish to consider to help them evaluate XNCR as an investment opportunity.
Xencor (NASDAQ:XNCR) shareholders are up 7.7% this past week, but still in the red over the last three yearsXencor, Inc. ( NASDAQ:XNCR ) shareholders should be happy to see the share price up 19% in the last month. But that is... |
Xencor to Present at the Piper Sandler 35th Annual Healthcare ConferencePASADENA, Calif., November 21, 2023--Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of patients with cancer and autoimmune diseases, today announced that company management will present at the Piper Sandler 35th Annual Healthcare Conference in New York City on Tuesday, November 28, 2023, at 8:00 a.m. ET / 11:00 a.m. PT. |
Things Look Grim For Xencor, Inc. (NASDAQ:XNCR) After Today's DowngradeOne thing we could say about the analysts on Xencor, Inc. ( NASDAQ:XNCR ) - they aren't optimistic, having just made a... |
Xencor, Inc. (NASDAQ:XNCR) Q3 2023 Earnings Call TranscriptXencor, Inc. (NASDAQ:XNCR) Q3 2023 Earnings Call Transcript November 8, 2023 Operator: Good afternoon and thank you for standing by. Welcome to Xencor’s Third Quarter 2023 Conference Call. Please be advised that this call is going to be recorded at the company’s request. Now, I would like to turn the call over to your speaker […] |
We're Not Very Worried About Xencor's (NASDAQ:XNCR) Cash Burn RateWe can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining... |
Xencor Reports Third Quarter 2023 Financial ResultsPASADENA, Calif., November 07, 2023--Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of patients with cancer and autoimmune diseases, today reported financial results for the third quarter ended September 30, 2023 and provided a review of recent business and clinical highlights. |
Xencor Sells Portion of Royalties and Milestones from Ultomiris® and Monjuvi® to OMERS Life Sciences for $215 MillionPASADENA, Calif., November 07, 2023--Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced the sale of portions of financial interests from Alexion Pharmaceuticals, Inc., on sales of Ultomiris® (ravulizumab-cwvz) and from MorphoSys AG on sales of Monjuvi® (U.S.)/Minjuvi® (ex-U.S.) (tafasitamab-cxix) to OMERS, one of Canada’s largest defined benefit pension plans. |
Xencor Presents Preclinical Data from Multiple XmAb® Research Programs at the SITC Annual MeetingPASADENA, Calif., November 03, 2023--Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of cancer and autoimmune diseases, today presented data from multiple preclinical-stage XmAb® programs at the 38th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) in San Diego. |
Xencor to Host Third Quarter 2023 Financial Results Webcast and Conference Call on November 7, 2023PASADENA, Calif., October 31, 2023--Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced it will release third quarter 2023 financial results after the market closes on Tuesday, November 7, 2023. |
Xencor (XNCR) Upgraded to Buy: What Does It Mean for the Stock?Xencor (XNCR) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy). |